List of Ciprodex drug patents

Ciprodex is owned by Novartis.

Ciprodex contains Ciprofloxacin; Dexamethasone.

Ciprodex has a total of 4 drug patents out of which 3 drug patents have expired.

Expired drug patents of Ciprodex are:

  • US9402805
  • US9149486
  • US9345714

Ciprodex was authorised for market use on 18 July, 2003.

Ciprodex is available in suspension/drops;otic dosage forms.

Ciprodex can be used as treatment of acute otitis media; treatment of acute otitis externa, treatment of acute otitis media.

The generics of Ciprodex are possible to be released after 04 June, 2025.

CIPRODEX's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9402805 NOVARTIS Method of treating middle ear infections
Sep, 2022

(6 months ago)

US9149486 NOVARTIS Method of treating middle ear infections
Sep, 2022

(6 months ago)

US9345714 NOVARTIS Method of treating middle ear infections
Sep, 2022

(6 months ago)

US8846650 NOVARTIS Method of treating middle ear infections
Jun, 2025

(2 years from now)

Drugs and Companies using CIPROFLOXACIN; DEXAMETHASONE ingredient

Market Authorisation Date: 18 July, 2003

Treatment: Treatment of acute otitis media; Treatment of acute otitis externa

Dosage: SUSPENSION/DROPS;OTIC

How can I launch a generic of CIPRODEX before it's patent expiration?
More Information on Dosage

CIPRODEX family patents

10

United States

1

Germany

1

Russia

1

Japan

1

Brazil

1

South Africa

1

Denmark

1

Austria

1

Canada

1

Mexico

1

Australia

1

Spain

1

Korea, Republic of

1

Poland

1

China

1

European Union

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic